SF3A3抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human testis tissue, Human prostate tissue, Primary antibody: P07822(ORM1 Antibody) at dilution 1/160, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07822(ORM1 Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

The SF3A3 antibody targets the SF3A3 protein, a critical component of the spliceosome complex responsible for pre-mRNA splicing. SF3A3 (Splicing Factor 3A Subunit 3) is part of the SF3A complex, which, along with SF3B, forms the U2 small nuclear ribonucleoprotein (snRNP) involved in recognizing branch site sequences during spliceosome assembly. This protein plays a vital role in maintaining splicing accuracy and regulating alternative splicing events, impacting gene expression diversity.

Antibodies against SF3A3 are widely used in research to study spliceosome dynamics, RNA processing mechanisms, and diseases linked to splicing dysregulation, such as cancers or neurodegenerative disorders. They enable detection of SF3A3 expression via techniques like Western blotting, immunofluorescence, or immunoprecipitation, helping to elucidate its localization, interactions, or expression levels under various conditions.

Many commercial SF3A3 antibodies are generated using recombinant proteins or peptide immunogens, with validation including specificity tests (e.g., siRNA knockdown or knockout controls) and cross-reactivity checks. Reliable antibodies are essential for investigating how SF3A3 mutations or dysregulation contribute to splicing errors and disease pathogenesis. Additionally, they support drug discovery efforts targeting spliceosome components, particularly in cancers where spliceosome inhibitors are being explored as therapies.